Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: A multi-phase power converter is described, which is configured to convert power between an input port and an output port. The multi-phase power converter comprises a basic switched converter comprising a basic inductor, wherein the basic switched converter is configured to convert power between the input port and the output port. Furthermore, the multi-phase power converter comprises an auxiliary switched converter comprising an auxiliary inductor, wherein the auxiliary switched converter is configured to convert power between the input port and an auxiliary port. In addition, the multi-phase power converter comprises a set of configuration switches configured to couple the auxiliary port to the output port, or to arrange the auxiliary inductor and the basic inductor in series.

Abstract: A voltage or current regulated power converter is presented. The power converter is configured to derive electrical power at an output voltage Vout at an output of the power converter from electrical power at an input voltage Vin at an input of the power converter, wherein the output voltage Vout is greater than or equal to the input voltage Vin. The power converter comprises an inductor, a plurality of capacitors and a plurality of switches. The input and output unit are coupled via an intermediate point, wherein the output unit comprises a first output or second output arrangement, and wherein the input unit comprises a first input or a second input arrangement. The power converter comprises a controller configured to control the plurality of switches such that a commutation cycle of the power converter comprises a plurality of different operation phases.

Abstract: A voltage or current regulated power converter is presented. The power converter is configured to derive electrical power at an output voltage Vout at an output of the power converter from electrical power at an input voltage Vin at an input of the power converter, wherein the output voltage Vout is greater than or equal to the input voltage Vin. The power converter comprises an inductor, a plurality of capacitors and a plurality of switches. The input and output unit are coupled via an intermediate point, wherein the output unit comprises a first output or second output arrangement, and wherein the input unit comprises a first input or a second input arrangement. The power converter comprises a controller configured to control the plurality of switches such that a commutation cycle of the power converter comprises a plurality of different operation phases.

Abstract: A charging system for a battery of an electronic device is described. The charging system comprises an adapter configured to derive a transfer current at a transfer voltage from a power source. Furthermore, the charging system comprises a battery charger configured to charge a battery of the electronic device with a battery current at a battery voltage using the transfer current at the transfer voltage. In addition, the charging system comprises power transmission means configured to transmit the transfer current at the transfer voltage to the battery charger. In addition, the charging system comprises communication means configured to transmit feedback information which is indicative of the battery voltage and/or battery current from the battery charger to the adapter. The adapter is configured to set the transfer voltage and/or transfer current in dependence of the feedback information.

Abstract: A voltage or current regulated power converter for charging batteries, is described. The power converter comprises an inductor (L), a capacitor cell (C1, C2), switches (S1, S2, S3, S4, S5, S6, S7, S8) and a controller. The controller controls the switches such that a commutation cycle of the power converter comprises a first phase, during which the capacitor cell and the inductor are arranged in series and during which a voltage across the serial arrangement of the capacitor cell and the inductor corresponds to Vin?Vout; a second phase, during which the capacitor cell and the inductor are arranged in series and during which the voltage across the serial arrangement of the capacitor cell and the inductor corresponds to ?Vout; and a third phase, during which the capacitor cell is floating and during which the voltage across the inductor corresponds to Vin?Vout or to ?Vout.

Abstract: A differential audio amplifier system and a related system to generate an output signal free or with only very limited clipping are disclosed. It provides a solution to solve the problem of limited electrical speaker amplifier output power available (e.g. inside battery driver applications). A differential speaker amplifier has positive and negative supply rails. In a first embodiment of the disclosure the negative supply rail is connected to the output of an inverting buck-boost converter and the positive supply rail is directly connected to VSS voltage. In a second embodiment of the disclosure the positive supply rail is connected to the output of a buck-boost converter and the negative supply rail is directly connected to a positive battery voltage.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

Abstract: The present document relates to power transformers for electronic computing devices. In particular, a power converter configured to convert electrical power at a DC input voltage Vin into electrical power at a DC output voltage is described. The power converter comprises a plurality of flying capacitors, and a plurality of switches which are configured to arrange the plurality of flying capacitors in accordance to a sequence of operation phases. The power converter comprises a control unit configured to control the plurality of switches to repeat the sequence of operation phases at a duty cycle frequency. The plurality of flying capacitors is arranged in series during the operation phases of the sequence of operation phases. The sequence of operation phases comprises at least two operation phases during which the plurality of flying capacitors is arranged in a different order.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Abstract: A differential audio amplifier system and a related system to generate an output signal free or with only very limited clipping are disclosed. It provides a solution to solve the problem of limited electrical speaker amplifier output power available (e.g. inside battery driver applications). A differential speaker amplifier has positive and negative supply rails. In a first embodiment of the disclosure the negative supply rail is connected to the output of an inverting buck-boost converter and the positive supply rail is directly connected to VSS voltage. In a second embodiment of the disclosure the positive supply rail is connected to the output of a buck-boost converter and the negative supply rail is directly connected to a positive battery voltage.

Abstract: The present invention relates to new salt forms of 5-(-2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, lartrate, phosphate and hemi fumarate slat thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-4-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

Abstract: This invention provides layout schemes for ball/pad regions on a printed circuit board for a small regular ball/pad region grid that provides additional space between ball/pad regions for increased wiring capability. The layout scheme is consistent with printed circuit board manufacturing requirements and minimum wiring channel requirements demanded by high density integrated circuit chips.

Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).

Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.